Genetic manipulation of drug sensitivity in haematopoietic cells

Expert Reviews in Molecular Medicine

Volumn 6, Issue 18, 2004, Pages

  Southgate, Thomas ^a   Fairbairn, Leslie J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Drug resistance; Gene therapy; Haematopoiesis; Haematopoietic stem cell; Haemopoiesis; Haemopoietic stem cell; HSC; Selection; Suicide gene therapy

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ALDEHYDE DEHYDROGENASE; ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; CYTOCHROME P450 2B6; DACARBAZINE; DACTINOMYCIN; DAUNORUBICIN; ETOPOSIDE; FLUCYTOSINE; FLUOROURACIL; GANCICLOVIR; GEMCITABINE; GLUTATHIONE TRANSFERASE; IRINOTECAN; MANGANESE SUPEROXIDE DISMUTASE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; OXAZAPHOSPHORINE DERIVATIVE; PACLITAXEL; PRODRUG; RETROVIRUS VECTOR; TEMOZOLOMIDE; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ALLOIMMUNITY; BONE MARROW TRANSPLANTATION; CANCER INFILTRATION; CARCINOGENESIS; CELL SELECTION; CLINICAL TRIAL; DRUG SENSITIVITY; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; GENETIC ENGINEERING; GENETIC MANIPULATION; GENETIC TRANSDUCTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIESIS; HEMATOPOIETIC CELL; HEMATOPOIETIC SYSTEM; HUMAN; IN VIVO STUDY; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUICIDE GENE THERAPY; T LYMPHOCYTE ACTIVATION; TUMOR VOLUME; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BIOLOGICAL MODEL; BONE MARROW CELL; DRUG RESISTANCE; ENZYMOLOGY; GENE; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; METHODOLOGY; PHYSIOLOGY; PROTEIN ENGINEERING; SUICIDE TRANSGENE;

VINCA;

ANIMALS; BONE MARROW CELLS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENES, MDR; GENES, TRANSGENIC, SUICIDE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MACROPHAGES; MODELS, BIOLOGICAL; PROTEIN ENGINEERING; TUMOR SUPPRESSOR PROTEINS;

EID: 31044449220     PISSN: 14623994     EISSN: None     Source Type: Journal    
DOI: 10.1017/S146239940400818X     Document Type: Review

References (172)

1. Rafferty, J.A. et al. (1996) Chemoprotection of normal tissues by transfer of drug resistance genes. Cancer Metastasis Rev 15, 365-383,
2. Kim, S.K. and Demetri, G.D. (1996) Chemotherapy and neutropenia. Hematol Oncol Clin North Am 10, 377-395,
3. Lowenthal, R.M. and Eaton, K. (1996) Toxicity of chemotherapy. Hematol Oncol Clin North Am 10, 967-990,
4. Testa, N.G. and Dexter, T.M. (1992) Colony-stimulating factors in the clinic. Curr Opin Biotechnol 3, 687-692,
5. Boogaerts, M.A. et al. (1996) Peripheral blood progenitor cell transplantation: where do we stand? Chairman's Summary of the European School of Oncology Task Force meeting Peripheral Blood progenitor cell's held September 29-30, 1995. Ann Oncol 7 Suppl 2, 1-4,
6. Dean, M., Rzhetsky, A. and Allikmets, R. (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11, 1156-1166,
7. Fardel, O., Lecureur, V. and Guillouzo, A. (1996) The P-glycoprotein multidrug transporter. Gen Pharmacol 27, 1283-1291,
8. Marie, J.P. and Legrand, O. (1999) MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol 457, 1-9,
9. Leonessa, F. and Clarke, R. (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10, 43-73,
10. Galski, H. et al. (1989) Expression of a human multidrug resistance cDNA (MDR1) in the bone marrow of transgenic mice: resistance to daunomycin-induced leukopenia. Mol Cell Biol 9, 4357-4363,
11. Mickisch, G.H. et al. (1991) Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity. Cancer Res 51, 5417-5424,
12. Mickisch, G.H. et al. (1992) Transplantation of bone marrow cells from transgenic mice expressing the human MDR1 gene results in long-term protection against the myelosuppressive effect of chemotherapy in mice. Blood 79, 1087-1093,
13. Guild, B.C. et al. (1988) Retroviral transfer of a murine cDNA for multidrug resistance confers pleiotropic drug resistance to cells without prior drug selection. Proc Natl Acad Sci U S A 85, 1595-1599,
14. Choi, K. et al. (1991) Multidrug resistance after retroviral transfer of the human MDR1 gene correlates with P-glycoprotein density in the plasma membrane and is not affected by cytotoxic selection. Proc Natl Acad Sci U S A 88, 7386-7390,
15. DelaFlor-Weiss, E. et al. (1992) Transfer and expression of the human multidrug resistance gene in mouse erythroleukemia cells. Blood 80, 3106-3111,
16. Podda, S. et al. (1992) Transfer and expression of the human multiple drug resistance gene into live mice. Proc Natl Acad Sci U S A 89, 9676-9680,
17. Hanania, E.G. and Deisseroth, A.B. (1994) Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1, 21-25,
18. Hanania, E.G. et al. (1995) Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther 2, 279-284,
19. Hegewisch-Becker, S. et al. (1995) Transduction of MDR1 into human and mouse haemopoietic progenitor cells: use of rhodamine (Rh123) to determine transduction frequency and in vivo selection. Br J Haematol 90, 876-883,
20. Hanania, E.G. and Deisseroth, A.B. (1997) Simultaneous genetic chemoprotection of normal marrow cells and genetic chemosensitization of breast cancer cells in a mouse cancer gene therapy model. Clin Cancer Res 3, 281-286,
21. Ward, M. et al. (1994) Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 84, 1408-1414,
22. Hanania, E.G. et al. (1996) Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A 93, 15346-15351,
23. Rahman, Z. et al. (1998) Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res 4, 2717-2721,
24. Devereux, S. et al. (1998) Feasibility of multidrug resistance (MDR-1) gene transfer in patients undergoing high-dose therapy and peripheral blood stem cell transplantation for lymphoma. Gene Ther 5, 403-408,
25. Hesdorffer, C. et al. (1998) Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. J Clin Oncol 16, 165-172,
26. Cowan, K.H. et al. (1999) Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. Clin Cancer Res 5, 1619-1628,
27. Moscow, J.A. et al. (1999) Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 94, 52-61,
28. Hennemann, B. et al. (1999) Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp, Hematol 27, 817-825,
29. Schilz, A.J. et al. (2000) MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions. Mol Ther 2, 609-618,
30. Moritz, T. et al. (1996) Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88, 855-862,
31. Kiem, H.P. et al. (1998) Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 92, 1878-1886,
32. Abonour, R. et al. (2000) Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6, 652-658,
33. Baum, C. et al. (1995) Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 69, 7541-7547,
34. Eckert, H.G. et al. (1996) High-dose multidrug resistance in primary human hematopoietic progenitor cells transduced with optimized retroviral vectors. Blood 88, 3407-3415,
35. Kiem, H.P. et al. (1997) Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood 90, 4638-4645,
36. Barquinero, J. et al. (2000) Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. Blood 95, 3085-3093,
37. van Hennik, P.B. et al. (1998) Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice. Blood 92, 4013-4022,
38. Schiedlmeier, B. et al. (2000) Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 95, 1237-1248,
39. Schiedlmeier, B. et al. (2002) Multidrug resistance 1 gene transfer can confer chemoprotection to human peripheral blood progenitor cells engrafted in immunodeficient mice. Hum Gene Ther 13, 233-242,
40. Knipper, R. et al. (2001) Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells. Gene Ther 8, 239-246,
41. Licht, T. et al. (2002) Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow. Proc Natl Acad Sci U S A 99, 3123-3128,
42. Bunting, K.D. et al. (1998) Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in transplanted mice. Blood 92, 2269-2279,
43. Margison, G.P. and Santibanez-Koref, M.F. (2002) O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 24, 255-266,
44. Margison, G.P. and O'Connor, P.J. (1990) Biological consequences of reactions with DNA: role of specific lesions. In Handbook of Experimental Pharmacology (Cooper, C.S. and Grover, P.L., eds), pp. 547-571, Springer-Verlag, Berlin
45. Brent, T.P. et al. (1993) Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase. Oncol Res 5, 83-86,
46. Middleton, M.R. et al. (1998) O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer 78, 1199-1202,
47. Brennand, J. and Margison, G.P. (1986) Reduction of the toxicity and mutagenicity of alkylating agents in mammalian cells harboring the Escherichia coli alkyltransferase gene. Proc Natl Acad Sci U S A 83, 6292-6296,
48. White, G.R. et al. (1986) Chinese hamster cells harbouring the Escherichia coli O6-alkylguanine alkyltransferase gene are less susceptible to sister chromatid exchange induction and chromosome damage by methylating agents. Carcinogenesis 7, 2077-2080,
49. Dumenco, L.L. et al. (1993) The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 259, 219-222,
50. Dumenco, L.L. et al. (1990) Transgenic mice expressing the bacterial O6 alkylguanine-DNA alkyltransferase gene: an animal model to study the role of DNA repair in the carcinogenesis of N-nitroso compounds. Prog Clin Biol Res 340A, 369-378,
51. Allay, J.A. et al. (1995) Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 85, 3342-3351,
52. Jelinek, J. et al. (1996) Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase. Blood 87, 1957-1961,
53. Moritz, T. et al. (1995) Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res 55, 2608-2614,
54. Maze, R. et al. (1996) Increasing DNA-repair methyltransferase levels via bone-marrow stem-cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci U S A 93, 206-210,
55. Allay, J.A., Davis, B.M. and Gerson, S.L. (1997) Human alkyltransferase-transduced murine myeloid progenitors are enriched in vivo by BCNU treatment of transplanted mice. Exp Hematol 25, 1069-1076,
56. Pegg, A.E. (1990) Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50, 6119-6129,
57. Srivenugopal, K.S. et al. (1996) Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 35, 1328-1334,
58. Lee, S.M. et al. (1993) Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 67, 1356-1360,
59. Lee, S.M. et al. (1993) Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67, 216-221,
60. Dolan, M.E. et al. (1993) Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 46, 285-290,
61. Friedman, H.S. et al. (1992) Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 84, 1926-1931,
62. Fairbairn, L.J. et al. (1995) O6-benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol 23, 112-116,
63. Gerson, S.L. et al. (1996) Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 88, 1649-1655,
64. Chinnasamy, N. et al. (1997) O6-benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 89, 1566-1573,
65. Friedman, H.S. et al. (2000) Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 18, 3522-3528,
66. Quinn, J.A. et al. (2002) Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 20, 2277-2283,
67. Elder, R.H., Margison, G.P. and Rafferty, J.A. (1994) Differential inactivation of mammalian and Escherichia coli O6-alkylguanine-DNA alkyltransferases by O6-benzylguanine. Biochem J 298 ( Pt 1), 231-235,
68. Harris, L.C. et al. (1995) Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity. Clin Cancer Res 1, 1359-1368,
69. Crone, T.M. et al. (1994) Mutations in human O6-alkylguanine-DNA alkyltransferase imparting resistance to O6-benzylguanine. Cancer Res 54, 6221-6227,
70. Davis, B.M. et al. (1999) Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Hum Gene Ther 10, 2769-2778,
71. Loktionova, N.A. and Pegg, A.E. (1996) Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N′-bis (2-chloroethyl)-N-nitrosourea. Cancer Res 56, 1578-1583,
72. Xu-Welliver, M., Kanugula, S. and Pegg, A.E. (1998) Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res 58, 1936-1945,
73. Hickson, I. et al. (1996) Protection of mammalian cells against chloroethylating agent toxicity by an O6-benzylguanine-resistant mutant of human O6-alkylguanine-DNA alkyltransferase. Gene Ther 3, 868-877,
74. Hickson, I. et al. (1998) Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene Ther 5, 835-841,
75. Davis, B.M. et al. (1997) Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 57, 5093-5099,
76. Chinnasamy, N. et al. (1998) Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene Ther 5, 842-847,
77. Ragg, S. et al. (2000) Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 60, 5187-5195,
78. Koc, O.N. et al. (1999) DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum Gene Ther 10, 1021-1030,
79. Frei III, E. and Eder, J.P. (2003) Principles of dose, schedule and combination therapy. In Cancer Medicine (6th edn) (Kufe, D.W. et al., eds), pp. 669-677, B.C. Decker, Hamilton, Ontario, Canada
80. Suzuki, M. et al. (1997) Retroviral coexpression of two different types of drug resistance genes to protect normal cells from combination chemotherapy. Clin Cancer Res 3, 947-954,
81. Suzuki, M., Sugimoto, Y. and Tsuruo, T. (1998) Efficient protection of cells from the genotoxicity of nitrosoureas by the retrovirus-mediated transfer of human O6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. Mutat Res 401, 133-141,
82. Jelinek, J. et al. (1999) A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents. Gene Ther 6, 1489-1493,
83. Galipeau, J. et al. (1997) A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs. Hum Gene Ther 8, 1773-1783,
84. Wang, J.S. et al. (2001) Genetic modification of hematopoietic progenitor cells for combined resistance to 4-hydroperoxycyclophosphamide, vincristine, and daunorubicin. Acta Pharmacol Sin 22, 949-955,
85. Vagner, S., Galy, B. and Pyronnet, S. (2001) Irresistible IRES. Attracting the translation machinery to internal ribosome entry sites. EMBO Rep 2, 893-898,
86. Hellen, C.U. and Sarnow, P. (2001) Internal ribosome entry sites in eukaryotic mRNA molecules. Genes Dev 15, 1593-1612,
87. Mizuguchi, H. et al. (2000) IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther 1, 376-382,
88. Sauerbrey, A. et al. (1999) Expression of a novel double-mutant dihydrofolate reductase-cytidine deaminase fusion gene confers resistance to both methotrexate and cytosine arabinoside. Hum Gene Ther 10, 2495-2504,
89. de Felipe, P. et al. (1999) Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. Gene Ther 6, 198-208,
90. Donnelly, M.L. et al. (2001) The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J Gen Virol 82, 1027-1041,
91. de Felipe, P. et al. (2003) Co-translational, intraribosomal cleavage of polypeptides; by the foot-and-mouth disease virus 2A peptide. J Biol Chem 278, 11441-11448,
92. Szymczak, A.L. et al. (2004) Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol 22, 589-594,
93. Cavazzana-Calvo, M. et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672,
94. Cavazzana-Calvo, M. et al. (2001) Gene therapy of severe combined immunodeficiencies. J Gene Med 3, 201-206,
95. Hacein-Bey-Abina, S., Fischer, A. and Cavazzana-Calvo, M. (2002) Gene therapy of X-linked severe combined immunodeficiency. Int J Hematol 76, 295-298,
96. Qasim, W., Gaspar, H.B. and Thrasher, A.J. (2004) Gene therapy for severe combined immune deficiency. Expert Rev Mol Med 6, 1-15,
97. Hobin, D.A. and Fairbairn, L.J. (2002) Genetic chemoprotection with mutant O6-alkylguanine-DNA-alkyltransferases. Curr Gene Ther 2, 1-8,
98. Sawai, N. et al. (2001) Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector. Mol Ther 3, 78-87,
99. Persons, D.A. et al. (2003) Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically-modified, drug-resistant hematopoietic stem cells. Blood
100. Gerson, S.L. (1993) Molecular epidemiology of therapy-related leukemias. Curr Opin Oncol 5, 136-144,
101. Blau, C.A., Neff, T. and Papayannopoulou, T. (1996) The hematological effects of folate analogs: implications for using the dihydrofolate reductase gene for in vivo selection. Hum Gene Ther 7, 2069-2078,
102. Allay, J.A. et al. (1997) Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 90, 3546-3554,
103. Allay, J.A. et al. (1998) In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 4, 1136-1143,
104. Persons, D.A. et al. (2004) Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 103, 796-803,
105. Zhou, S. et al. (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7, 1028-1034,
106. Scharenberg, C.W., Harkey, M.A. and Torok-Storb, B. (2002) The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. Blood 99, 507-512,
107. Sugimoto, Y. et al. (2003) Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. J Gene Med 5, 366-376,
108. Jansen, M. et al. (2002) Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells. Cancer Gene Ther 9, 737-746,
109. Davis, B.M., Koc, O.N. and Gerson, S.L. (2000) Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. Blood 95, 3078-3084,
110. Neff, T. et al. (2003) Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 112, 1581-1588,
111. Greco, O. and Dachs, G.U. (2001) Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 187, 22-36,
112. Springer, C.J. and Niculescu-Duvaz, I. (2000) Prodrug-activating systems in suicide gene therapy. J Clin Invest 105, 1161-1167,
113. Riddell, S.R. et al. (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2, 216-223,
114. Freeman, S.M., Ramesh, R. and Marrogi, A.J. (1997) Immune system in suicide-gene therapy. Lancet 349, 2-3,
115. Danks, M.K. et al. (1999) Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clin Cancer Res 5, 917-924,
116. Fillat, C. et al. (2003) Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther 3, 13-26,
117. Appelbaum, F.R. (2003) The current status of hematopoietic cell transplantation. Annu Rev Med 54, 491-512,
118. Ho, V.T. and Soiffer, R.J. (2001) The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98, 3192-3204,
119. Horowitz, M.M. et al. (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562,
120. Helene, M. et al. (1997) Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene. J Immunol 158, 5079-5082,
121. Cohen, J.L. et al. (1997) Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes. Blood 89, 4636-4645,
122. Bordignon, C. et al. (1995) Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 6, 813-819,
123. Bonini, C. et al. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724,
124. Tiberghien, P. et al. (2001) Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood 97, 63-72,
125. Garin, M.I. et al. (2001) Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 97, 122-129,
126. Chalmers, D. et al. (2001) Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene. Mol Ther 4, 146-148,
127. Black, M.E., Kokoris, M.S. and Sabo, P. (2001) Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res 61, 3022-3026,
128. Qasim, W. et al. (2002) T cell transduction and suicide with an enhanced mutant thymidine kinase. Gene Ther 9, 824-827,
129. Ferrand, C. et al. (2000) Retrovirus-mediated gene transfer in primary T lymphocytes: influence of the transduction/selection process and of ex vivo expansion on the T cell receptor beta chain hypervariable region repertoire. Hum Gene Ther 11, 1151-1164,
130. Marktel, S. et al. (2003) Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101, 1290-1298,
131. Qasim, W. et al. (2003) The impact of retroviral suicide gene transduction procedures on T cells. Br J Haematol 123, 712-719,
132. Vigna, E. and Naldini, L. (2000) Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2, 308-316,
133. Cavalieri, S. et al. (2003) Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102, 497-505,
134. Cohen, J.L., Boyer, O. and Klatzmann, D. (2001) Suicide gene therapy of graft-versus-host disease: immune reconstitution with transplanted mature T cells. Blood 98, 2071-2076,
135. Drobyski, W.R. et al. (2001) Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. Blood 97, 2506-2513,
136. Litvinova, E. et al. (2002) Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease. Blood 100, 2020-2025,
137. Burke, B. et al. (2002) Macrophages in gene therapy: cellular delivery vehicles and in vivo targets. J Leukoc Biol 72, 417-428,
138. Michon, J. et al. (1995) In vivo targeting of human neuroblastoma xenograft by anti-GD2/anti-Fc gamma RI (CD64) bispecific antibody. Eur J Cancer 31A, 631-636,
139. Russoniello, C. et al. (1998) Characterization of a novel bispecific antibody that mediates Fcgamma receptor type I-dependent killing of tumor-associated glycoprotein-72-expressing tumor cells. Clin Cancer Res 4, 2237-2243,
140. Burke, B. et al. (2003) Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol 163, 1233-1243,
141. Zelzer, E. et al. (1998) Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1alpha/ARNT. Embo J 17, 5085-5094,
142. Treins, C. et al. (2002) Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 277, 27975-27981,
143. Jung, Y.J. et al. (2003) IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. Faseb J 17, 2115-2117,
144. Jung, Y. et al. (2003) Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. Biochem J 370, 1011-1017,
145. Jaffar, M., Williams, K.J. and Stratford, I.J. (2001) Bioreductive and gene therapy approaches to hypoxic diseases. Adv Drug Deliv Rev 53, 217-228,
146. Patterson, A.V. et al. (2002) Oxygen-sensitive enzyme-prodrug gene therapy for the eradication of radiation-resistant solid tumours. Gene Ther 9, 946-954,
147. De Palma, M. et al. (2003) Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. Nat Med 9, 789-795,
148. Baum, C. and Fehse, B. (2003) Mutagenesis by retroviral transgene insertion: risk assessment and potential alternatives. Curr Opin Mol Ther 5, 458-462,
149. Hacein-Bey-Abina, S. et al. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348, 255-256,
150. Hacein-Bey-Abina, S. et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419,
151. Li, Z. et al. (2002) Murine leukemia induced by retroviral gene marking. Science 296, 497,
152. Sellers, S.E. et al. (2001) The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. Blood 97, 1888-1891,
153. Heyworth, C.M. et al. (2002) Retroviral transfer and expression of human MDR-1 in a murine haemopoietic stem cell line does not alter factor dependence, growth or differentiation characteristics. Leukemia 16, 106-111,
154. Yamada, T. et al. (2003) Suppression of intestinal polyposis in Mdr1-deficient ApcMin/ + mice. Cancer Res 63, 895-901,
155. Kustikova, O.S. et al. (2003) Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102, 3934-3937,
156. Baum, C. et al. (2004) Chance or necessity? Insertional Mutagenesis in Gene Therapy and Its Consequences. Mol Ther 9, 5-13,
157. Baum, C. et al. (2003) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101, 2099-2114,
158. Rohdewohld, H. et al. (1987) Retrovirus integration and chromatin structure: Moloney murine leukemia proviral integration sites map near DNase I-hypersensitive sites. J Virol 61, 336-343,
159. Wu, X. et al. (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751,
160. Nakai, H. et al. (2003) AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34, 297-302,
161. Schroder, A.R. et al. (2002) HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529,
162. Lindahl, T. (2000) Suppression of spontaneous mutagenesis in human cells by DNA base excision-repair. Mutat Res 462, 129-135,
163. Sladek, N.E. (1999) Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines. Curr Pharm Des 5, 607-625,
164. Townsend, D.M. and Tew, K.D. (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369-7375,
165. Epperly, M.W. et al. (2003) Mitochondrial localization of superoxide dismutase is required for decreasing radiation-induced cellular damage. Radiat Res 160, 568-578,
166. Capiaux, G.M. et al. (2003) Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-Fluorouracil. Hum Gene Ther 14, 435-446,
167. Momparler, R.L. et al. (1996) Transfection of murine fibroblast cells with human cytidine deaminase cDNA confers resistance to cytosine arabinoside. Anticancer Drugs 7, 266-274,
168. Danks, M.K. and Potter, P.M. (2004) Enzyme-prodrug systems: carboxylesterase/CPT-11. Methods Mol Med 90, 247-262,
169. Niculescu-Duvaz, D. et al. (2003) Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 (CPG2) showing large cytotoxicity differentials in GDEPT. J Med Chem 46, 1690-1705,
170. Kan, O., Kingsman, S. and Naylor, S. (2002) Cytochrome P450-based cancer gene therapy: current status. Expert Opin Biol Ther 2, 857-868,
171. Brown, N.L. and Lemoine, N.R. (2004) Clinical trials with GDEPT: cytosine deaminase and 5-fluorocytosine. Methods Mol Med 90, 451-458,
172. Denny, W.A. (2002) Nitroreductase-based GDEPT. Curr Pharm Des 8, 1349-1361,